Accepted for Publication: September 13, 2022.
Published Online: November 7, 2022. doi:10.1001/jamainternmed.2022.4969
Corresponding Author: Ilana B. Richman, MD, MHS, Yale School of Medicine, 367 Cedar St, Room 301a, New Haven, CT 06511 (email@example.com).
Author Contributions: Mr Potnis and Dr Richman had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Potnis, Ross, Gross, Richman.
Acquisition, analysis, or interpretation of data: Potnis, Ross, Aneja, Richman.
Drafting of the manuscript: Potnis, Richman.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Richman.
Obtained funding: Richman.
Supervision: Gross, Richman.
Conflict of Interest Disclosures: Mr Potnis reported grants from the US National Institutes of Health (NIH) and grants from the American Society of Hematology outside the submitted work. Dr Ross reported grants from the US Food and Drug Administration, Johnson & Johnson, the Medical Devices Innovation Consortium, Agency for Healthcare Research and Quality (AHRQ), grants from the NIH and Arnold Ventures outside the submitted work; and serving as an expert witness at the request of Relator’s attorneys in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen, all outside the submitted work. Dr Aneja reported grants from the US National Science Foundation, from the US National Cancer Institute (NCI), Patterson Family Trust, American Society of Clinical Oncology, the Radiation Society of North America, the American Cancer Society, and AHRQ, and nonfinancial support from Amazon, all outside the submitted work. Dr Gross reported grants from Johnson & Johnson, funding from AstraZeneca, and personal fees from Genentech outside the submitted work. Dr Richman reported funding from the NCI and salary support from the Centers for Medicare & Medicaid Services outside of the submitted work. No other disclosures were reported.
Funding/Support: Dr Richman received funding for this study from the US National Institutes of Health (No. K08 CA248725).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
K , Geppert
J , Stinton
et al. Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy. BMJ
. 2021;374:n1872. doi:10.1136/bmj.n1872
LR , Lehman
CD , Gastounioti
A , Conant
EF , Bahl
M . Artificial Intelligence (AI) for screening mammography, from the AJR
Special Series on AI Applications. AJR Am J Roentgenol
. 2022;219(3):369-380. doi:10.2214/AJR.21.27071
AW , Marinovich
ML , Houssami
et al. Independent external validation of artificial intelligence algorithms for automated interpretation of screening mammography: a systematic review. J Am Coll Radiol
. 2022;19(2 Pt A):259-273. doi:10.1016/j.jacr.2021.11.008
N , Kirkpatrick-Jones
G , Noguchi
N , Lee
CI . Artificial Intelligence (AI) for the early detection of breast cancer: a scoping review to assess AI’s potential in breast screening practice. Expert Rev Med Devices
. 2019;16(5):351-362. doi:10.1080/17434440.2019.1610387PubMedGoogle ScholarCrossref
F , Elkin
M , Josiah Macy
J , Bordaz
V , Weymouth
W . Detection of radiographic abnormalities in mammograms by means of optical scanning and computer analysis. Radiology
. 1967;89(2):211-215. doi:10.1148/89.2.211Google ScholarCrossref
GS , Haygood
TM , Stephens
TW , Whitman
GJ , Bovik
AC , Markey
MK . Computer-aided detection of breast cancer—have all bases been covered? Breast Cancer (Auckl)
. 2008;2:5-9.PubMedGoogle Scholar
CD , Wellman
RD , Buist
DS , Kerlikowske
K , Tosteson
AN , Miglioretti
DL ; Breast Cancer Surveillance Consortium. Diagnostic accuracy of digital screening mammography with and without computer-aided detection. JAMA Intern Med
. 2015;175(11):1828-1837. doi:10.1001/jamainternmed.2015.5231
MZ , Umrao
S , Chang
et al. Using adversarial images to assess the robustness of deep learning models trained on diagnostic images in oncology. JCO Clin Cancer Inform
. 2022;6:e2100170. doi:10.1200/CCI.21.00170
BH , Hicks
DF , Payabvash
et al. Multi-institutional validation of deep learning for pretreatment identification of extranodal extension in head and neck squamous cell carcinoma. J Clin Oncol
. 2020;38(12):1304-1311. doi:10.1200/JCO.19.02031
US Food and Drug Administration. Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions. 2020. Accessed August 1, 2022. https://www.fda.gov/media/77642/download
US Food and Drug Administration. Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device. 2019. Accessed August 1, 2022. https://www.fda.gov/media/122535/download
K , Su
Y-R , Sprague
et al. Association of screening with digital breast tomosynthesis vs digital mammography with risk of interval invasive and advanced breast cancer. JAMA
. 2022;327(22):2220-2230. doi:10.1001/jama.2022.7672
C , McCaskill-Stevens
W . Tomosynthesis Mammographic Imaging Screening Trial (TMIST): an invitation and opportunity for the national medical association community to shape the future of precision screening for breast cancer. J Natl Med Assoc
. 2020;112(6):613-618. doi:10.1016/j.jnma.2020.05.021